Hexarelin vs Tesamorelin: What the Research Shows
Hexarelin and Tesamorelin side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Hexarelin if…
- you want a human GH-release study: hexarelin stimulated GH secretion in patients with idiopathic GH deficiency[12]
- you are tested in sport and want to avoid a WADA-prohibited substance: WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin (check hexarelin's own status separately)[2]
Consider Tesamorelin if…
- you want a product with an FDA label: Egrifta is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management[5]
- you want randomized data in HIV-associated lipodystrophy: Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment.[11]
Spec comparison
Showing 10 of 11 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.
| Field | Hexarelin | Tesamorelin |
|---|---|---|
| Class | Growth hormone releasing peptide (GHRP) | GHRH analog |
| Also called | — | tesa, Egrifta |
| FDA status | Not FDA approved · research chemical | FDA approved (Egrifta) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | No WADA record in our data | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | [half-life by route] | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) |
| Evidence strength | [evidence grade] | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 |
| Human studies we summarised | [n] | 12 human (11 randomized or controlled) of 16 summarised |
| Typical study doses | [dose range] |
|
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
A challenge test versus placebo-controlled treatment trials
Hexarelin's human data cited here is a challenge study of the GH response to intravenous doses (2 micrograms/kg) in children and adults with GH deficiency.[12]
Tesamorelin was tested as a treatment: in a dose-ranging placebo-controlled trial of HIV-infected patients with central fat, it was given subcutaneously once daily for 12 weeks at 1 or 2 mg.[13]
In that dose-ranging trial, IGF-I rose by 48% at 1 mg and 65% at 2 mg versus placebo.[13]
A meta-analysis of tesamorelin in HIV lipodystrophy pooled 909 patients and found 2 mg reduced waist circumference and trunk fat while raising lean body mass.[14]
The meta-analysis also found growth-hormone-related adverse effects and higher discontinuation rates on tesamorelin, though the discontinuation difference was not statistically conclusive.[14]
Status and handling
Tesamorelin is a labelled product, Egrifta, and the label is clear that it is not for weight loss management.[5]
A doping-control paper developed urine extraction and mass-spectrometric detection for GHRP-1, GHRP-2, GHRP-4, GHRP-5, GHRP-6, alexamorelin, ipamorelin and hexarelin.[15]
Common questions
Hexarelin vs tesamorelin: which burns fat?
In tesamorelin's dose-ranging trial, trunk fat decreased in the 2 mg group versus placebo. Hexarelin's human study cited here measured GH release only.[13]
Is hexarelin FDA approved?
A cached review says most GH-releasing peptides, apart from GHRP-2, are nonapproved pharmaceuticals.[16]
Do hexarelin and tesamorelin both raise IGF-I?
Tesamorelin did, in a dose-related way in HIV patients, whereas the hexarelin study we have measured acute GH and cortisol responses.[13]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 5EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 7Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 8The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 9PubMed search: (hexarelin[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.Endocrine · 2015PMID 25645463Accessed 2 Oct 2026
- 11Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 12The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.The Journal of clinical endocrinology and metabolism · 1995PMID 7673411Accessed 2 Oct 2026
- 13A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England) · 2005PMID 16052083Accessed 2 Oct 2026
- 14Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026
- 15Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry.Analytical and bioanalytical chemistry · 2011PMID 21298258Accessed 2 Oct 2026
- 16Metabolism of growth hormone releasing peptides.Analytical chemistry · 2012PMID 23101768Accessed 2 Oct 2026
Found an error? Report a correction.